Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Dermatology

Harnessing Light for Health: Evaluating the Gro...

In recent years, the rapid development of technology and innovation has sped up the transformation of the healthcare and well-being industry. Among the various emerging and evolving trends, Light T...

Aug 30, 2023

chronic-spontaneous-urticaria-csu-treatment
Towards a Promising Future: Unveiling Advancements in Chronic Spontaneous Urticaria (CSU) Treatment

Chronic urticarial is a common skin condition characterized by itchy, wheal-and-flare skin reactions or hives. As per Delveinsight analysts, in 2022, there were around 776K individuals in the US affected by chronic urticaria. It can be spontaneous or inducible, lasting more than 6 weeks and persisting for over a ye...

Find More
ycanth-approval-for-molluscum-contagiosum-treatment
Will Verrica’s YCANTH Approval Change the Molluscum Contagiosum Treatment Dynamics?

Molluscum contagiosum, which affects around 6 million individuals in the United States, predominantly children, is a highly contagious viral skin disease characterized by unique, raised pinkish lesions that are irritating and often painful. These lumps can also cause inflammation and raise the risk of infection in ...

Find More
Nutricosmetics Market Outlook
Evaluating the Evolving Trends in the Nutricosmetics Market: The Intersection of Nutrition and Skincare

The desire for natural beauty that can improve one's health and appearance without having any negative side effects is rising as consumers are becoming more cautious about the food they eat and the products they introduce into their bodies. Nutricosmetics are one such category of product that fit with the modern cu...

Find More

More Views & Analysis

Pharma News for Pfizer, Sarepta, FibroGen, Erasca
FDA Approves Jardiance for Type 2 Diabetes; FDA Approves Pfizer’s LITFULO for Alopecia Areata; Sarepta Therapeutics’s ELEVIDYS Approval; Tonix Pharmaceuticals to Acquire Two Migraine Products from Upsher-Smith; FibroGen’s Phase 3 ZEPHYRUS-1 Study of Pamrevlumab; FDA Orphan Drug Designation to ERAS-801 for Malignant Glioma

FDA Approves Jardiance for the Treatment of Type 2 Diabetes in Children 10 Years and Older Boehringer Ingelheim and Eli Lilly and Company announced that the FDA has approved Jardiance® (empagliflozin) 10 mg and 25 mg tablets to decrease blood sugar together with diet and exercise in children 10 years and older w...

Find More

Pharma News for GSK, Roche, Avita, Ipsen
FDA Extended the Review Period for Momelotinib; FDA Approves Roche’s Columvi; Avita Medical Obtains FDA Approval of RECELL; FDA Approves Odevixibat for ALGS; TME Pharma Receives IND Approval for NOX-A12; Aldeyra’s Phase 3 INVIGORATE‑2 Trial of Reproxalap

GSK Announces Extension of FDA Review Period for Momelotinib After all, GSK will not hear from the FDA this month about its marketing application for momelotinib as a therapy for anemia in myelofibrosis patients. The pharmaceutical company announced that the US Food and Drug Administration has extended the drug'...

Find More

Gene Therapies for Dystrophic Epidermolysis Bullosa
Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?

Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by changes in the COL7A1 gene. In this rare condition, blisters form on the skin and the moist inner lining of some organs and body cavities. Depending upon the nature of the inheritance pattern, dystrophic epidermolysis bullosa is divided into ...

Find More

Pharma News for Kyverna, Annovis, Astellas, FibroGen
FDA Fast Track Status to Kyverna’s KYV-101; Annovis’s Phase III Study for Buntanetap; Gilteritinib Demonstrated Benefit in AML Patients; FDA Orphan Drug Designation to DTx Pharma’s DTx-1252; FibroGen’s LELANTOS-1 Phase 3 Clinical Study Result

FDA Grants Fast Track Status to KYV-101 for Refractory Lupus Nephritis Treatment Kyverna Therapeutics announced that the FDA has given Fast Track status to KYV-101, a treatment for patients suffering from resistant lupus nephritis (LN). KYV-101 is an innovative therapy that uses anti-CD19 chimeric antigen recept...

Find More

MedTech News for Eosolutions, Grünenthal, Orlucent
Eosolutions Corp’s Dr. Banner Balloon Guide Catheter; US FDA Approves the Cyltezo® Pen; Orlucent’s Handheld Mole Imaging System; Grünenthal’s Resiniferatoxin for Pain Associated with Knee Osteoarthritis; Element Science’s Jewel Patch Wearable Cardioverter Defibrillator; A.Menarini Diagnostics’s PRIME MDx Platform

Eosolutions Announces The Full Commercial Launch of The Dr. Banner Balloon Guide Catheter EOSolutions Corp., a forerunner in medical technology focused on offering high-quality catheter solutions, is pleased to introduce the Dr. Banner, Balloon Guide Catheter (BGC). Dr. Banner, developed in collaboration with In...

Find More

Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases
Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

The role and application of Artificial Intelligence have grown at an immense pace in recent years. Globally, several companies including large & small scale businesses, education, retail, and telecommunications, among others are actively exploring opportunities to leverage the potential of AI in their organizat...

Find More

Peanut Allergy accounts for the majority of severe food-associated allergic reactions. It is strictl.....

Find More

Acute Respiratory Distress Syndrome (ARDS) is a serious lung condition that causes low blood oxygen......

Find More

Alopecia Areata (AA) is an autoimmune disorder that leads to hair loss on the scalp, face, and on ot.....

Find More

Tinnitus is a condition where a person experiences different kinds of noises in one or both ears. It.....

Find More

Though appear rare, rare diseases are far from being rare. With over 7,000 rare disease affecting mi.....

Find More

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD.....

Find More